<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1390-7794</journal-id>
<journal-title><![CDATA[Ius Humani. Revista de Derecho]]></journal-title>
<abbrev-journal-title><![CDATA[Ius Humani]]></abbrev-journal-title>
<issn>1390-7794</issn>
<publisher>
<publisher-name><![CDATA[Universidad Hemisferios]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1390-77942020000200251</article-id>
<article-id pub-id-type="doi">10.31207/ih.v9i2.254</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Theoretical problems of legal regulation of innovations in the medical field: experience in counteracting covid-19]]></article-title>
<article-title xml:lang="es"><![CDATA[Problemas teóricos de la regulación legal de las innovaciones en el cuidado de la salud: experiencia de contrarrestar el covid-19]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fedorov]]></surname>
<given-names><![CDATA[Valentyn]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kravchenko]]></surname>
<given-names><![CDATA[Sergii]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Reznichenko]]></surname>
<given-names><![CDATA[Hanna]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Opara]]></surname>
<given-names><![CDATA[Nataliia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tsybokhin]]></surname>
<given-names><![CDATA[Oleg]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,National University &#8220;Odesa Law Academy&#8221;  ]]></institution>
<addr-line><![CDATA[Odesa ]]></addr-line>
<country>Ukraine</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,National University &#8220;Odesa Law Academy&#8221;  ]]></institution>
<addr-line><![CDATA[Odesa ]]></addr-line>
<country>Ukraine</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Odesa State University of Internal Affairs  ]]></institution>
<addr-line><![CDATA[Odesa ]]></addr-line>
<country>Ukraine</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,National University &#8220;Odesa Law Academy&#8221;  ]]></institution>
<addr-line><![CDATA[Odesa ]]></addr-line>
<country>Ukraine</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,National University &#8220;Odesa Law Academy&#8221;  ]]></institution>
<addr-line><![CDATA[Odesa ]]></addr-line>
<country>Ukraine</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>9</volume>
<numero>2</numero>
<fpage>251</fpage>
<lpage>289</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.senescyt.gob.ec/scielo.php?script=sci_arttext&amp;pid=S1390-77942020000200251&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.senescyt.gob.ec/scielo.php?script=sci_abstract&amp;pid=S1390-77942020000200251&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.senescyt.gob.ec/scielo.php?script=sci_pdf&amp;pid=S1390-77942020000200251&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: The work is devoted to identifying the main problems of legal regulation of innovations in the medical field and developing the best options for solving them in the context of the Covid-19 pandemic. Thus, the research methodology is based on general and special scientific methods, in particular: formal legal, historical and legal, comparative analysis, and modeling. So, the procedure and issues to be considered are as follows. In the introduction, we will briefly highlight the origins of intellectual property rights issues in the medical field and the overall state of the pharmaceutical industry. In the first subsection of the third section, we will consider the positions of the main players in the pharmaceutical industry and the contradictions between them. In the second subsection, we will highlight the international obligations under TRIPS. In the third subsection, we will consider the consequences of their direct violation. In the fourth subsection, the impact of Covid-19 and the methods of legal regulation of medical innovations and patents under the TRIPS agreement will be discussed. In the fifth subsection, we will propose a way out and a compromise according to the Indian scenario. As a result of the study, contradictions were identified in the aspect of maintaining the balance of private and public interests between states and international pharmaceutical companies in the context of a pandemic and proposed ways to resolve them within the existing legal methods under the TRIPS agreement to achieve an acceptable compromise.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: El artículo está dedicado a identificar los principales problemas de regulación legal de las innovaciones en el campo médico y desarrollar las mejores opciones para solucionarlos en el contexto de la pandemia Covid-19. Esta investigación utiliza los métodos científicos generales y especiales, en particular: formal legal, histórico y legal, análisis comparativo y modelización. Se consideran las siguientes cuestiones, en el siguiente orden. En la introducción, se mencionan los orígenes de los problemas de derechos de propiedad intelectual en el campo médico y el estado general de la industria farmacéutica. En la primera subsección de la tercera sección, consideraremos las posiciones de los principales actores de la industria farmacéutica y las contradicciones entre ellos. En la segunda subsección, destacaremos las obligaciones internacionales bajo los ADPIC. En la tercera subsección, consideraremos las consecuencias de su violación directa. En la cuarta subsección, se discutirá el impacto de Covid-19 y los métodos de regulación legal de las innovaciones médicas y las patentes bajo el acuerdo ADPIC. En la quinta subsección, propondremos una salida y un compromiso de acuerdo con el escenario indio. Como resultado del estudio, se identificaron contradicciones en el aspecto de mantener el equilibrio de los intereses públicos y privados entre los estados y las empresas farmacéuticas internacionales en el contexto de una pandemia y se propusieron formas de resolverlas dentro de los métodos legales existentes en el marco del acuerdo ADPIC para lograr un compromiso aceptable.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Innovation]]></kwd>
<kwd lng="en"><![CDATA[Coronavirus]]></kwd>
<kwd lng="en"><![CDATA[Intellectual Property]]></kwd>
<kwd lng="en"><![CDATA[Health]]></kwd>
<kwd lng="en"><![CDATA[TRIPS Agreement]]></kwd>
<kwd lng="es"><![CDATA[Innovación]]></kwd>
<kwd lng="es"><![CDATA[Coronavirus]]></kwd>
<kwd lng="es"><![CDATA[propiedad intelectual]]></kwd>
<kwd lng="es"><![CDATA[salud]]></kwd>
<kwd lng="es"><![CDATA[Acuerdo sobre los ADPIC]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<collab>Agencia Tributaria</collab>
<source><![CDATA[Analysis of the EU Regulation n° 608/2013 of 12 June 2013 on customs enforcement of intellectual property rights, which repeals Council Regulation (EU) n° 1383/2003. Analysis of the implementation Regulation of the European Commission n° 1352/2013.]]></source>
<year>n.d</year>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buletsa]]></surname>
<given-names><![CDATA[S. B]]></given-names>
</name>
</person-group>
<source><![CDATA[Features of the contract of controlled access in the conditions of Covid-19.]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<collab>Canada. Supreme Court</collab>
<source><![CDATA[AstraZeneca Canada Inc. v. Apotex Inc.: Judgment]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chepis]]></surname>
<given-names><![CDATA[O. I]]></given-names>
</name>
</person-group>
<source><![CDATA[Ensuring the balance of interests of right holders and society in the application of compulsory licensing in the conditions of Covid-19]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chibisov]]></surname>
<given-names><![CDATA[D. M]]></given-names>
</name>
</person-group>
<source><![CDATA[Protection of intellectual property rights within the World Trade Organization]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Odesa ]]></publisher-loc>
<publisher-name><![CDATA[Phoenix]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Is the rise in drug prices again the fault of the monopolies?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chirikhin]]></surname>
<given-names><![CDATA[S. N]]></given-names>
</name>
</person-group>
<source><![CDATA[All-Russian economic journal ECO]]></source>
<year>2009</year>
<volume>1</volume>
<page-range>36-50</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<collab>Curia Europa</collab>
<source><![CDATA[PTC Therapeutics International v. EMA; MSD Animal Health Innovation and Intervet International v. EMA]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Childhood Vaccine Purchase Costs in the Public Sector: Past Trends, Future Expectations]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[M. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmerman]]></surname>
<given-names><![CDATA[J. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Wheeler]]></surname>
<given-names><![CDATA[J. R. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Freed]]></surname>
<given-names><![CDATA[F. L]]></given-names>
</name>
</person-group>
<source><![CDATA[American Journal of Public Health]]></source>
<year>2002</year>
<volume>92</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1982-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="">
<collab>Delo.UA</collab>
<source><![CDATA[Pharmacy chains create a monopoly, and 80% of drug supplies to Ukraine are controlled by 3 distributors]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Methods of treatment as objects of patent law: world experience]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ennan]]></surname>
<given-names><![CDATA[R.E]]></given-names>
</name>
</person-group>
<source><![CDATA[Problems of legal regulation of civil relations in terms of Covid-19]]></source>
<year>2020</year>
<volume>1</volume>
<page-range>41-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="">
<collab>European Commission</collab>
<source><![CDATA[Directive 2001/83/EC]]></source>
<year>2001</year>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="">
<collab>European Parliament</collab>
<source><![CDATA[Regulation (EC) n° 726/2004]]></source>
<year>2004</year>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Big Pharma&#8217;s Go-To Defense of Soaring Drug Prices Doesn&#8217;t Add Up]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ezekiel]]></surname>
<given-names><![CDATA[L. E]]></given-names>
</name>
</person-group>
<source><![CDATA[The Atlantic]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrario]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kanavos]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Managed entry agreements for pharmaceuticals: the European experience]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Brussels ]]></publisher-loc>
<publisher-name><![CDATA[EMiNet]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrario]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Araja]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Bochenek]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Catic]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Danko]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Dimitrova]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Furst]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Greiciute-Kuprijanov]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Hoxha]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Jakupi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Laidmae11]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Loblova]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[´ Mardare]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Markovic-Pekovic]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Meshkov]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Novakovic]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Petrova]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Pomorski]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Tomek]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Voncina]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Haycox]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kanavos]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Bonanno]]></surname>
<given-names><![CDATA[P.V.]]></given-names>
</name>
<name>
<surname><![CDATA[Godman]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<source><![CDATA[PharmacoEconomics]]></source>
<year>2017</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="">
<collab>Finland</collab>
<collab>Ukraine</collab>
<source><![CDATA[Treaty between the Government of Ukraine and the Government of the Republic of Finland on the promotion and mutual protection of investments.]]></source>
<year>2004</year>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="">
<collab>Gilead Sciences Inc</collab>
<collab>Ukraine</collab>
<source><![CDATA[]]></source>
<year>1996</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="">
<collab>Global Affairs Canada</collab>
<source><![CDATA[Eli Lilly and Company v. Government of Canada]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The method is the main object of patent law in the pharmaceutical industry]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gritsyk]]></surname>
<given-names><![CDATA[A. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Stasiv]]></surname>
<given-names><![CDATA[T. G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Problems of modern medical science]]></source>
<year>2006</year>
<volume>1</volume>
<page-range>45-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Supreme Court of Canada Rejects the Promise of the Patent Doctrine.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heckman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Gowling WLG]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[House report accuses Trump administration of &#8216;waste, fraud or abuse&#8217; in U.S. ventilator contract.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins-Dunn]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<source><![CDATA[CNBC]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[In the Matter of C &amp; W&#8217;s Application for a Patent. Reports of Patent]]></article-title>
<source><![CDATA[Design and Trade Mark Cases]]></source>
<year>1914</year>
<volume>31</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>235-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="">
<collab>India</collab>
<source><![CDATA[Patent Act]]></source>
<year>1970</year>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="">
<collab>Interfax Ukraine</collab>
<source><![CDATA[PJSC &#8220;Farmak&#8221; supported the resolution to support the draft law n° 9385]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="">
<collab>Interfax Ukraine</collab>
<source><![CDATA[Top 10 largest pharmacy chains will consolidate up to 70% of the market over the next few years-forecast]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="">
<collab>Interfax-Ukraine</collab>
<source><![CDATA[Compulsory licensing of drugs to combat coronavirus can be a &#8220;Pandora&#8217;s box&#8221; for the pharmaceutical market-a lawyer]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Opinion: Big pharma is taking big money from U.S. taxpayers to find a coronavirus vaccine-and charge whatever they want for it]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jorge]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Market Watch]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="">
<collab>Joshi Attorneys</collab>
<source><![CDATA[Changes in India&#8217;s Patent Law]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="">
<collab>Kaiser Family Foundation</collab>
<source><![CDATA[Most Say They Can Afford Their Prescription Drugs, But One in Four Say Paying is Difficult, Including More Than Four in Ten People Who are Sick.]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compulsory licensing of medicines: EU experience]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kashintseva]]></surname>
<given-names><![CDATA[O. Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Theory and practice of intellectual property]]></source>
<year>2017</year>
<volume>3</volume>
<page-range>38-42</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kharytonova]]></surname>
<given-names><![CDATA[O. I.]]></given-names>
</name>
</person-group>
<source><![CDATA[On the use of off-label drugs (out of instructions) and compassionate use (for reasons of humanity), Covid-19, and new opportunities and challenges in the context of intellectual property protection]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Forced import substitution, or where does TRIPS + lead?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirichenko]]></surname>
<given-names><![CDATA[I. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Lexology]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacy market of Ukraine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirsanov]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Helicopter View]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The global hunt for a coronavirus drug]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuchler]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Inagaki]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Neville]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Financial Times]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Parallel imports-an important mechanism for the existence of competitive relations. Scientific notes of NaUKMA]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuzmenko]]></surname>
<given-names><![CDATA[L.G]]></given-names>
</name>
</person-group>
<source><![CDATA[Economic Sciences]]></source>
<year>2016</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>95-100</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Parallel import as a portal to the parallel world]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyrychenko]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Apteka online]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prices for Covid-19 Vaccines are starting to come into Focus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lupkin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Health News from NPR]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Here&#8217;s How to Get Discounted (Or Even Free) Flu Shots This Year]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marsh]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<source><![CDATA[Goodrx]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intellectual property in the field of medicines in the context of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazurenko]]></surname>
<given-names><![CDATA[S. V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Problems of legal regulation of civil relations in terms of Covid-19]]></source>
<year>2020</year>
<volume>1</volume>
<page-range>50-8</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Theoretical preconditions and practical aspects of parallel import in the system of realization of intellectual property rights to medicines.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moskalyuk]]></surname>
<given-names><![CDATA[N. B]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of the Academy of Advocacy of Ukraine]]></source>
<year>2013</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[German Government Plans Possibilities to Limit Patents In View of Corona Pandemic]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Musmann]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Kluwer Patent Blog]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Patent Strategies in Pharmaceuticals: Patent Greening]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orlova]]></surname>
<given-names><![CDATA[&#1040;]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of the Intellectual Property Rights Court]]></source>
<year>2019</year>
<volume>26</volume>
<page-range>83-9</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="">
<collab>PharmaTimes</collab>
<source><![CDATA[Novartis loses Indian Glivec patent case.]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="">
<collab>RBK Ukraine</collab>
<source><![CDATA[A bill on criminal liability for overpricing of medicines to be submitted to the Rada]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="">
<collab>Research Institute of Intellectual Property of the National Academy of Legal Sciences of Ukraine</collab>
<source><![CDATA[The committee of the Verkhovna Rada of Ukraine supports the bill on the implementation of the provisions of the EU legislation in the field of IP]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Processing of personal data under the new rules: protection or violation of human rights.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Senyuta]]></surname>
<given-names><![CDATA[I. Ya]]></given-names>
</name>
</person-group>
<source><![CDATA[Higher School of Advocacy NAAU]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Would-be coronavirus drugs are cheap to make]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Service]]></surname>
<given-names><![CDATA[R. F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Science]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[How to break the collusion of doctors and pharmacists?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shcherbina]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[UkrRudProm]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Drug Patent System in India and its Application]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shirsat]]></surname>
<given-names><![CDATA[M.K]]></given-names>
</name>
</person-group>
<source><![CDATA[Asian Journal of Pharmaceutical and Clinical Research]]></source>
<year>2011</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-24</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The pharmaceutical industry is able to meet the needs of Ukrainians in medicines during a pandemic]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shymkiv]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[UkrInform]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[AbbVie will allow generic copies of its HIV pill in Israel after the government approved a license]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverman]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Statnews]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Oxfam America People over profits: Make Covid-19 medicines and vaccines free and fair for all]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverman]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Lusiani]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Oxfam International]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Coronavirus, a Brescia manca una valvola per i rianimatori: ingegneri e fisici la stampano in 3D in sei ore.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sparaciari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Business insider Italia]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Covid-19, respirators and patents for industrial designs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tomarov]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Vasyl Kisil Law Firm]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="">
<collab>U.S. Government Accountability Office (GAO)</collab>
<source><![CDATA[Drug industry: Profits, Research and Development Spending, and Merger and Acquisition Deals]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="">
<collab>Ukraine</collab>
<source><![CDATA[Fundamentals of Ukrainian Legislation on Health Care]]></source>
<year>1993</year>
</nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="">
<collab>Ukraine</collab>
<source><![CDATA[On protection of rights to inventions and utility models: Law 3687-XII.]]></source>
<year>1993</year>
</nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="">
<collab>Ukraine</collab>
<source><![CDATA[On protection of rights to inventions and utility models: Law 3687-XII.]]></source>
<year>1993</year>
</nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="">
<collab>Ukraine</collab>
<source><![CDATA[On protection of industrial design rights: Law]]></source>
<year>1994</year>
</nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="">
<collab>Ukraine</collab>
<source><![CDATA[On Amendments to Certain Legislative Acts of Ukraine Concerning the Implementation of Certain Provisions of European Union Legislation in the Field of Intellectual Property: Draft Law 9385.]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="">
<collab>Ukraine</collab>
<source><![CDATA[On Amendments to Certain Laws of Ukraine Concerning the Treatment of Coronavirus Disease (Covid-19): Law 539-IX]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B62">
<nlm-citation citation-type="">
<collab>Ukraine. Cabinet of Ministers of Ukraine</collab>
<source><![CDATA[On approval of the Procedure for granting permission by the to use a patented invention (utility model)]]></source>
<year>2004</year>
</nlm-citation>
</ref>
<ref id="B63">
<nlm-citation citation-type="">
<collab>Ukraine. Cabinet of Ministers</collab>
<source><![CDATA[Some issues of procurement of goods, works and services necessary for the implementation of measures aimed at preventing the occurrence and spread, localization and elimination of outbreaks, epidemics and pandemics of acute respiratory disease Covid-19 caused by coronavirus SARS-CoV-2 in Ukraine: Resolution 225.]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B64">
<nlm-citation citation-type="">
<collab>Ukraine. Economic Court of Kyiv</collab>
<source><![CDATA[Judgment in case n° 910/4881/18]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B65">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Police expose a group of pharmaceutical companies in bribing doctors for 140 million hryvnias]]></article-title>
<collab>Ukraine. National Police</collab>
<source><![CDATA[Official Site of National Police]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B66">
<nlm-citation citation-type="">
<collab>United Nations</collab>
<source><![CDATA[Doha Declaration on Financing for Development: Outcome of the International Conference on the Follow-up to Financing for Development to Review Progress in the Implementation of the Monterrey Consensus]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B67">
<nlm-citation citation-type="">
<collab>United States of America</collab>
<collab>Ukraine</collab>
<source><![CDATA[Treaty between Ukraine and the United States of America on the promotion and mutual protection of investments]]></source>
<year>1994</year>
</nlm-citation>
</ref>
<ref id="B68">
<nlm-citation citation-type="">
<collab>USAID</collab>
<source><![CDATA[The results of the study &#8220;(Not)expensive medicine&#8221;]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B69">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Performance-based managed entry agreements for new medicines in OECD countries and EU member states. How they work and possible improvements going forward]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wenzl]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Health Working Papers OECD]]></source>
<year>2019</year>
<volume>115</volume>
<page-range>4-5</page-range></nlm-citation>
</ref>
<ref id="B70">
<nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Remuneration guidelines for non-voluntary use of a patent on medical technologies]]></source>
<year>2005</year>
</nlm-citation>
</ref>
<ref id="B71">
<nlm-citation citation-type="">
<collab>World Intellectual Property Organization</collab>
<source><![CDATA[Paris Convention for the Protection of Industrial Property]]></source>
<year>1883</year>
</nlm-citation>
</ref>
<ref id="B72">
<nlm-citation citation-type="">
<collab>World Trade Organization</collab>
<source><![CDATA[Trade-Related Aspects of Intellectual Property Rights]]></source>
<year>1994</year>
</nlm-citation>
</ref>
<ref id="B73">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Managed access agreements&#8221; for innovative medicines to ensure the availability of drugs in European countries]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zaliska]]></surname>
<given-names><![CDATA[O.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Stasiv]]></surname>
<given-names><![CDATA[H.-O. I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Apteka]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B74">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antimonopoly Committee of Ukraine and the pharmaceutical market: pressure or protection?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheltikhin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Legal Newspaper Online.]]></source>
<year>2018</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
